Trial Profile

A multi-center, randomized, double-blind, phase IIb placebo-controlled study for PAH treatment

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IKT 001PRO (Primary)
Indications Pulmonary arterial hypertension
Focus Therapeutic Use
Acronyms IMPROVE-PAH

Most Recent Events

06 Nov 2025 New trial record
14 Aug 2025 According to a Inhibikase Therapeutics media, company will be finalizing clinical study protocol for forthcoming phase 2b study, and feature an interim safety review for study continuance by the Data Safety Monitoring Board after at least 50 patients have completed 12 weeks of follow-up. The Company expects to initiate this trial in the second half of 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com